Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03718910 · ClinicalTrials.gov registry record

DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

A clinical trial of Autism Spectrum Disorder and DDX3X, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
10
Enrollment target
1
Study location

NCT03718910: Recruiting study of Autism Spectrum Disorder and DDX3X, sponsored by Icahn School of Medicine at Mount Sinai.

NCT03718910 is a study of Autism Spectrum Disorder and DDX3X that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 10 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03718910, a study of Autism Spectrum Disorder and DDX3X, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
10 participants
Enrollment target
1
Study location

Study Summary

DDX3X syndrome is a genetic cause of intellectual disability and other neurologic features including, in some cases, autism. Variants in the DDX3X gene are thought to account for 1-3% of unexplained intellectual disability in females, making it one of the more common causes of intellectual disability.This study seeks to characterize DDX3X-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

Primary Outcome

The ADOS is a structured, play-based assessment of communication, social interaction and behavior in individuals (children and adults) suspected of having a diagnosis of Autism Spectrum Disorder. The examiner will select 1 of 4 different ADOS modules, which differ based on chronological age and verbal fluency, to use for the individual being assessed. An Overall Total score \>= 16, if the individual meets for the "few to no words" algorithm, or 12, if the individual meets for the "some words" al

Study Locations (1)

New York

  • The Seaver Autism Center for Research and Treatment - New York

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2018-05-22
Est. Completion 2026-05

What NCT03718910 shows while recruiting

NCT03718910 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (93% lower).

The record links to 3 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT03718910 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03718910 about?

NCT03718910 is a clinical study titled "DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.". DDX3X syndrome is a genetic cause of intellectual disability and other neurologic features including, in some cases, autism. Variants in the DDX3X gene are thought to account for 1-3% of unexplained intellectual disability in females, making it one of the more common causes of intellectual disabilit...

What is the current status of trial NCT03718910?

This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2018-05-22. Estimated completion is 2026-05.

What conditions does trial NCT03718910 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder, DDX3X, Mental Retardation, X-linked 102.

Who is sponsoring clinical trial NCT03718910?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03718910 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03718910's enrollment target sits among peer trials

10 216th of 224 higher than 5 of 224 other Autism Spectrum Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03718910, the US trial registry maintained by the National Library of Medicine. NCT03718910 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.